1
2
3
4 Development of HepG2-derived cells expressing cytochrome P450s for
5
6 assessing metabolism-associated drug-induced liver toxicity
7
8

9 Jiekun Xuan¹, Si Chen¹, Baitang Ning², William H. Tolleson¹, Lei Guo^{1,*}
10

11 ¹ Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food
12 and Drug Administration, Jefferson, AR 72079, USA
13

14 ² Division of System Biology, National Center for Toxicological Research, U.S. Food and
15 Drug Administration, Jefferson, AR 72079, USA
16

17 *To whom correspondence should be addressed: 3900 NCTR Road, Jefferson, AR 72079,
18 USA. Tel: +1 (870) 543-7048; Email: Lei.Guo@fda.hhs.gov
19
20

21 Key words: drug-induced liver toxicity; HepG2; drug metabolizing enzyme; cytochrome
22 P450s
23

24 Running title: HepG2 expressing CYPs
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

ABSTRACT

The generation of reactive metabolites from therapeutic agents is one of the major mechanisms of drug-induced liver injury (DILI). In order to evaluate metabolism-related toxicity and improve drug efficacy and safety, we generated a battery of HepG2-derived cell lines that express 14 cytochrome P450s (CYPs) (1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5 and 3A7) individually using a lentiviral expression system. The expression/production of a specific CYP in each cell line was confirmed by an increased abundance of the CYP at both mRNA and protein levels. Moreover, the enzymatic activities of representative CYPs in the corresponding cell lines were also measured. Using our CYP-expressed HepG2 cells, the toxicity of three drugs that could induce DILI (amiodarone, chlorpromazine and primaquine) was assessed, and all of them showed altered (increased or decreased) toxicity compared to the toxicity in drug-treated wild-type HepG2 cells. CYP-mediated drug toxicity examined in our cell system is consistent with previous reports, demonstrating the potential of these cells for assessing metabolism-related drug toxicity. This cell system provides a practical *in vitro* approach for drug metabolism screening and for early detection of drug toxicity. It is also a surrogate enzyme source for the enzymatic characterization of a particular CYP that contributes to drug-induced liver toxicity.

1. Introduction

Drug-induced liver injury (DILI) is a leading cause of drug failures in clinical trials and the major reason of drug withdrawals from the market [1]. Identification of drugs that cause liver injury at the early stage of drug development poses a challenge to both the pharmaceutical industry and the U.S. Food and Drug Administration (FDA). Preclinical testing is one of the important approaches to early detect drug toxicity, and there is a constant need for the development of improved tools to facilitate toxicity assessment and risk identification.

The causes of DILI are multifactorial, including toxic effects caused by reactive metabolites, reactive oxygen species, inflammatory reactions, mitochondrial dysfunction, and imbalances between cellular damage and protective responses [1-5]. Metabolism-related toxicity is generally mediated by the generation of reactive metabolites from non-toxic parenteral compounds, particularly *via* cytochrome P450 (CYP) enzyme pathways [6]. The inter-individual variability in the expression of drug metabolizing genes predisposes certain individuals to increased susceptibility to DILI [7, 8]. Therefore, it is important to examine the roles of drug metabolizing enzymes and identify specific metabolizing enzymes that contribute to drug-induced liver toxicity.

Numerous *in vitro* models, such as recombinant enzymes, liver microsomes, liver cytosolic fractions, hepatic cells, liver slices and isolated perfused livers, have been used to examine drug-related hepatotoxicity [9]. Traditionally, cell-based assays have been performed using human primary hepatocytes, either freshly isolated or cryopreserved, to evaluate drug metabolism and drug-drug interactions [10, 11]. Indeed, the application of primary human hepatocytes in drug metabolism and toxicity studies is considered as a “gold standard”, because, under appropriate conditions, these cells retain functional activity of the major drug-metabolizing enzymes [12]. However, phenotypic instability, short life span, batch-to-batch variation and limited availability of primary human hepatocytes constrain their broad use.

Human hepatoma cell lines, such as HepG2, Hep3B, and Huh7, have been widely used in toxicity screening and mechanistic studies, owing to their high stability, unlimited life-span and ready availability. However, lower or no expression of the majority of drug-metabolizing genes is the most critical drawback associated with using these cell lines for drug metabolism and toxicity studies [13, 14]. As a strategy to overcome this limitation, genetically modified hepatic cell lines expressing human drug metabolizing genes have been developed and used for assessing drug metabolism and toxicity. For example, using adenoviral or lentiviral infection systems, cells that transiently or stably express individual CYPs, such as CYP1A1, CYP2C8, CYP2C9 or CYP3A4, have been generated [15-18]. These cells responded appropriately to known toxic chemicals, demonstrating their values for toxicity testing and mechanistic studies. However, not all of them are publicly available.

1
2
3
4 In this study, we aimed to develop a comprehensive set of cell lines that express the major
5 human CYPs individually, to provide surrogate hepatic cell lines for the study of metabolism-
6 mediated drug hepatotoxicity and the identification of specific CYP isoforms responsible for the
7 metabolism of a drug. Toward this goal, using the lentiviral expression system, HepG2-derived
8 cell lines expressing 14 individual CYPs (1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19,
9 2D6, 2E1, 3A4, 3A5 and 3A7) were generated, and the functionality of these CYPs was
10 confirmed at the mRNA, protein, and enzymatic activity levels. In addition, three drugs that
11 could cause metabolism-mediated DILI were examined to evaluate the utility of these cells in
12 drug metabolism and toxicity screening.
13
14
15
16
17
18
19

20 **2. Materials and Methods**

21 *2.1. Chemicals and reagents*

22
23
24
25 Dulbecco's modified Eagle's medium (DMEM), amiodarone hydrochloride, chlorpromazine
26 hydrochloride, primaquine biphosphate and dimethyl sulfoxide (DMSO) were purchased from
27 Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was from Atlanta Biologicals
28 (Lawrenceville, GA). Blasticidin S hydrochloride and antibiotic-antimycotic were from Life
29 Technologies (Grand Island, NY).
30
31
32

33 *2.2. Cell culture*

34
35
36 The human hepatocellular carcinoma cell line HepG2 was purchased from American Type
37 Culture Collection (ATCC; Manassas, VA). HepG2 cells were routinely cultured in high-glucose
38 DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25
39 µg/ml fungizone. Stably transduced HepG2 cells were maintained in the above growth medium
40 supplemented with 2.5 µg/ml blasticidin. The 293T cell line required for lentiviral packaging was
41 obtained from Biosettia Inc. (San Diego, CA) and propagated in high-glucose DMEM
42 supplemented with 10% FBS, 1% penicillin/streptomycin/fungizone, 1 mM sodium pyruvate and
43 0.1 mM non-essential amino acids. All cells were grown at 37 °C in a humidified atmosphere
44 with 5% CO₂. Unless otherwise described, cells were seeded at a density of 3~5 × 10⁵ cells/ml
45 in 96-well tissue culture plates, 60-mm or 10-cm tissue culture dishes. Cells were allowed to
46 adhere for 24 h prior to treatment with drugs or DMSO vehicle.
47
48
49
50
51

52 *2.3. Construction of CYP-expressing HepG2 cell lines*

53
54
55 A total of 14 human CYP cDNAs either amplified from cDNA libraries or prepared by gene
56 synthesis were individually subcloned into the lentiviral expression vector pLV-EF1α-MCS-
57 IRES-Bsd (Biosettia) along with an in-frame c-Myc extension added to the carboxyl terminus of
58 each recombinant CYP protein. The identities and structures of each of recombinant CYP
59 expression vectors were confirmed by nucleotide sequencing. The sequencing primers used are
60
61
62
63
64
65

shown in Table 1. EF1 α -3' and IRES-5' are primers for 5'- and 3'-ends of the CYP gene inserts, respectively. For lentivirus production, 293T cells were seeded at a density of 1.0×10^6 cells per well in 6-well tissue culture plates and incubated overnight. On the following day, each of the 14 recombinant lentiviral CYP expression vector as well as the lentiviral control vector was co-transfected with three lentiviral packaging vectors (pVSV-G, pRSV-Rev, pMDLg/pRRE) into the cultured 293T cells per well using lipotransfectamine 2000 reagent (Life Technologies). After 48 hours post-transfection, lentiviral supernatants were harvested from each well, filtered through 0.45 μ m cellulose acetate filters and stored at -80 °C. Lentiviral titers were determined by infection of HepG2 cells with serial dilutions of lentiviral stocks followed by blasticidin selection. The titers ranged between 10^6 and 10^7 infectious units per milliliter. For lentiviral transduction, HepG2 cells were grown to 10-25% confluence in 6-well tissue culture plates, and infectious lentiviral particles were added to cell cultures at a multiplicity of infection of 10 with 4 μ g/ml polybrene (Sigma). Transduced cells were selected in the presence of 10 μ g/ml blasticidin to generate HepG2 cell lines expressing individual CYPs or the control vector.

2.4. RNA extraction and cDNA Synthesis

Total RNA was extracted from cells using the RNeasy Mini kit (Qiagen, Valencia, CA). The quantity and purity of RNA were measured with a NanoDrop 8000 spectrophotometer (Thermo Scientific, Wilmington, DE). RNA quality was assessed on an Agilent 2100 Bioanalyzer using the RNA 6000 Nano assay (Agilent Technologies, Palo Alto, CA). For mRNA quantification, cDNA was synthesized from 1 μ g of total RNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.

2.5. Quantitative real-time PCR

Quantitative real-time PCR was used to examine the expression of individual CYP enzymes in HepG2 cell lines at the mRNA level. Reactions were performed in a 10- μ l volume according to the manufacturer's protocol of FastStart Universal Probe Master (Rox) (Roche Applied Science, Indianapolis, IN) using a ViiA™ 7 Real-Time PCR system (Applied Biosystems) under the following conditions: 10 min at 95 °C followed by 40 cycles of 15 s at 95 °C, and 1 min at 60 °C. The following TaqMan probes (Applied Biosystems) were used: human *CYP1A1* (Hs01054797_g1), human *CYP1A2* (Hs00167927_m1), human *CYP1B1* (Hs00164383_m1), human *CYP2A6* (Hs00868409_s1), human *CYP2B6* (Hs03044634_m1), human *CYP2C8* (Hs02383390_s1), human *CYP2C9* (Hs04260376_m1), human *CYP2C18* (Hs00426403_m1), human *CYP2C19* (Hs00426380_m1), human *CYP2D6* (Hs00164385_m1), human *CYP2E1* (Hs00559368_m1), human *CYP3A4* (Hs00604506_m1), human *CYP3A5* (Hs00241417_m1), human *CYP3A7* (Hs00426361_m1), and human β -actin (ACTB, Hs99999903_m1). The comparative threshold cycle (Ct) method [19] was used to determine the relative expression levels of target genes. Ct values were normalized to that of the endogenous control β -actin.

2.6 Western blotting

Western blotting was performed using whole-cell lysates prepared in RIPA buffer (150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 25mM Tris•HCl pH 7.6) containing Halt protease inhibitor cocktail (Thermo Scientific). The protein concentrations of the lysates were measured using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). Equivalent amounts of total protein were resolved by SDS-PAGE and immunoblotted with a mouse monoclonal anti-Myc-tag antibody (Cell Signaling Technology, Danvers, MA) followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G (IgG; Santa Cruz Biotechnology, Santa Cruz, CA) to confirm CYP protein expression. GAPDH (Santa Cruz Biotechnology) was used to verify equal protein loading.

2.7 CYP activity assay

CYP enzyme activities were measured using P450-Glo assays (Promega, Madison, WI). Briefly, lentivirus-transduced cells were seeded at a density of 5×10^4 cells per well in 96-well white wall/clear bottom tissue culture plates and incubated overnight. Cells in triplicate wells were washed with PBS and incubated with the appropriate cell permeable luminogenic substrates (100 μ M luciferin 6'-chloroethyl ether for CYP1A1 and CYP1B1, 6 μ M luciferin-1A2 for CYP1A2, 3 μ M luciferin-2B6 for CYP2B6, 150 μ M luciferin 6'-methyl ether for CYP2C8, 100 μ M 6'-deoxyluciferin for CYP2C9, 10 μ M ethylene glycol ester of 6'-deoxyluciferin for CYP2C19, 30 μ M ethylene glycol ester of luciferin 6'-methyl ether for CYP2D6, and 3 μ M luciferin isopropyl acetal for CYP3A) prepared in 100 μ l fresh media or PBS at 37 °C for 30 min-4 h (isoform dependent). A selective inhibitor of CYP1A, alpha-naphthoflavone (10 μ M), was pre-incubated with cells prior to the addition of luciferin-ME, luciferin-H EGE and luciferin ME EGE, to reduce non-specific enzymatic reactions in appropriate cases. Luminescence was generated in separate 96-well white plates by addition of 25 μ l luciferin detection reagent to an equal volume of supernatants collected from treated cells and incubation for 20 min at room temperature. Luminescent signals were measured with a Synergy 2 multi-mode microplate reader (BioTek, Winooski, VT). Background luminescence determined in a set of empty wells containing no cells was subtracted from sample measurements. The number of viable cells remaining in the original 96-well plates was determined by the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI), and the luminescence measurements obtained using P450-Glo assays were normalized to the viable cell number to represent enzymatic activities.

2.8 Cytotoxicity assay

Cells were seeded at a density of 5×10^4 cells per well in 100 μ l medium in 96-well white wall/clear bottom plates and incubated overnight. Two-fold serial dilutions of the test drugs were prepared and added to the culture medium. The maximum concentrations used in the cytotoxicity assay were at least 100-fold of the therapeutic $C_{\max}$ (*i.e.*, maximum therapeutic plasma concentration), which was considered a reasonable threshold to differentiate

1
2
3
4 hepatotoxic drugs from non-hepatotoxic drugs. Lower concentrations were used if a cytotoxic
5 effect was observed at the lowest concentration initially tested. Cell viability was determined at
6 the end of a 24-h drug exposure period using the CellTiter-Glo assay (Promega). The
7 luminescence was measured using a microplate reader (BioTek). DMSO was used as a vehicle
8 control and the final DMSO concentration in the medium was $\leq 0.5\%$ (v/v). The percentage of
9 cell viability at each drug concentration was calculated using the formula: % cell viability =
10 (luminescence of drug-treated cells/luminescence of vehicle-treated cells) $\times 100$.
11
12
13
14

15 *2.9 Statistical analysis*

16
17 All data analyses were carried out using GraphPad Prism 5 (GraphPad Software, San Diego,
18 CA). Comparisons of two groups were performed by two-tailed unpaired Student's *t*-test. The
19 statistical significance level was set at $p < 0.05$.
20
21
22
23
24

25 **3. Results and Discussion**

26
27 The central role of the liver in the metabolism and clearance of drugs makes it a major target of
28 drug toxicity. A large number of drugs have been reported to cause hepatotoxicity, posing a
29 profound challenge to the pharmaceutical industry and regulatory agencies [20, 21]. Although
30 the mechanisms underlying drug-induced hepatotoxicity remain poorly understood, it has been
31 widely accepted that in many cases the initial step triggering the progression of hepatotoxicity
32 involves metabolism of a drug to chemically reactive metabolites, which covalently bind to
33 cellular macromolecules (e.g., proteins, nucleic acids and lipids), resulting in irreversible
34 chemical modification, adduct formation and functional impairment [22-24].
35
36
37
38
39

40 Human hepatoma cell lines are commonly used *in vitro* models in hepatotoxicity studies due to
41 their ready accessibility, phenotypic stability and unlimited proliferative capacity. However, most
42 hepatoma cell lines express low levels of drug-metabolizing enzymes, particularly CYP
43 enzymes, hampering their use in drug metabolism studies. To confer metabolic competence to
44 those cell lines, new cell models that transiently [15-17, 25-27] or stably [18] overexpress
45 heterologous CYP enzymes have been developed and successfully used in toxicity studies. Of
46 these models, HepG2 is the most widely used host cell line for transfection/transduction, since it
47 retains many liver-specific biosynthetic functions, including those for metabolizing activities [28].
48 Importantly, HepG2 cells express considerable endogenous levels of NADPH-P450 reductase
49 and cytochrome *b₅*, which are electron transport components required for CYP activity [29].
50 Recombinant lentivirus is a widely used gene carrier, and the efficient delivery of transgenes *via*
51 lentiviral vectors to HepG2 cells has been reported [30-32]. In the present study, we developed
52 a panel of metabolically competent HepG2 cell lines by lentiviral-mediated transduction with
53 expression vectors encoding individual human CYP isoforms. To our knowledge, this panel of
54
55
56
57
58
59
60
61
62
63
64
65

hepatic cell lines expresses the most comprehensive set of individual human CYPs described thus far for a noncommercial source.

3.1. Establishment of HepG2-derived cells expressing CYPs

In this study, a recombinant lentivirus system was used to ensure efficient transduction and expression of CYP cDNAs. CYP gene expression was driven by the human EF1 α promoter, a house-keeping gene whose promoter is insensitive to transcriptional silencing *via* DNA methylation [33]. In total, 15 stably transduced HepG2 cell lines were generated, including 14 cell lines transduced with individual CYP cDNAs and another containing an empty vector alone (referred to as EV controls). CYP expression in each HepG2 cell line was characterized. Significantly increased expression of each CYP mRNA in the corresponding cell line was detected by quantitative real-time PCR (Fig. 1A). The average increase in CYP mRNA levels after transduction is about 1.9×10^5 fold, with a ~12-fold difference between the highest and lowest fold changes. The expression of each CYP protein in the corresponding cell line was confirmed by western blotting (Fig. 1B). To examine the functionality of our expression system, the activities of representative CYP isoforms were measured by P450-Glo assays using luminogenic substrates. Compared with EV-transduced control cells, HepG2 cells transduced with CYP cDNAs showed significant increases in enzymatic activity. The fold changes in CYP activity are 92.5 ± 8.9 (CYP1A1), 87.7 ± 5.9 (CYP1A2), 77.6 ± 3.4 (CYP1B1), 71.0 ± 6.0 (CYP2B6), 56.9 ± 1.1 (CYP2C8), 67.9 ± 3.4 (CYP2C9), 47.6 ± 2.4 (CYP2C19), 52.9 ± 2.7 (CYP2D6), 95.9 ± 2.4 (CYP3A4), 68.1 ± 5.6 (CYP3A5), and 50.6 ± 3.4 (CYP3A7), respectively. These results indicate that we have developed a panel of HepG2-derived cell lines that express much higher levels of the introduced human CYPs than HepG2 parental cells. The cytotoxic effects of representative drugs were further assessed in the established cell lines.

3.2. Cytotoxic effects of amiodarone

Amiodarone, an iodinated benzofuran derivative, is one of the most commonly prescribed antiarrhythmic drugs [34]. Despite its effectiveness in the treatment of a broad spectrum of arrhythmias, amiodarone has numerous side effects, including pulmonary toxicity, thyroid toxicity, hepatotoxicity and other types of organ toxicity [35]. Hepatotoxicity, as manifested by liver enzyme abnormalities, has been reported in 14-82% of patients treated with amiodarone [36]. Although the hepatic side effects are generally mild and reversible, they frequently result in drug discontinuation [37]. Fatal cases have occasionally been reported [36, 38], and the prevalence of severe liver injury is estimated at 1-3% [36].

Amiodarone has been considered as a most-DILI-concern drug [39]. The maximum plasma concentration (C_{max}) of amiodarone is about 0.85 μ M at a therapeutic dose of 400 mg in healthy subjects [40]. In our study, significant cytotoxicity of amiodarone was observed in EV controls at 12.5 μ M or higher concentrations (Fig. 2A). Cell viability was remarkably decreased by amiodarone exposure in HepG2 cells overexpressing CYP1A1 or CYP3A4 compared to EV

controls, indicating cytotoxic effects due to metabolic activation of amiodarone by these two CYP enzymes. In contrast, cytotoxicity of amiodarone was significantly decreased by the overexpression of other CYP isoforms, except CYP2D6, suggesting that these metabolizing enzymes may contribute to the detoxification of amiodarone. Interestingly, CYP isoforms in the same subfamily may play opposite roles in the metabolism of amiodarone. While the overproduction of CYP1A1 enhanced the cytotoxic effect of amiodarone, the overexpression of CYP1A2 reduced its cytotoxic effect; likewise, whereas the overproduction of CYP3A4 increased the cytotoxic effect, CYP3A5 and CYP3A7 decreased such effect.

Amiodarone is primarily metabolized to mono-*N*-desethylamiodarone (DEA) in humans [41]. DEA is highly lipophilic and widely distributed in organ tissues, particularly in liver and lung [42]. It has been shown that DEA is more toxic to hepatocytes than amiodarone and may contribute to the amiodarone-associated hepatotoxicity, most likely by inhibiting the respiratory chain and producing oxidative stress [43, 44]. A high ratio of DEA/aminodarone in the plasma and liver is considered as a risk factor for hepatotoxicity [45]. There is evidence demonstrating that CYP1A1 and CYP3A4 are the most efficient enzymes transforming amiodarone to DEA and the former isoform has higher potency [46], which is consistent with the results of our cytotoxicity assays. Several other CYP isoforms, including CYP1A2, CYP2C8, CYP2C19, and CYP2D6, have also been involved in DEA production in humans, but we found that the overexpression of these metabolizing enzymes did not increase but even decreased the cytotoxicity of amiodarone, suggesting that they may contribute, even more significantly, in the detoxification of DEA. Recent studies have reported that the active metabolite DEA can be further transformed by hydroxylation to 3'-OH-*N*-desethylamiodarone, dealkylation to di-*N*-desethylamiodarone and deamination to amiodarone-EtOH, and various CYP isoforms are involved in the elimination of DEA [47, 48]. Further studies are needed to elucidate whether these three minor metabolites of amiodarone are associated with detoxification pathways and to identify the CYPs involved in their formation.

3.3. Cytotoxic effects of chlorpromazine

Chlorpromazine, a dimethylamine derivative of phenothiazine, is one of the four antipsychotic drugs on the World Health Organization (WHO) essential medicine list [49]. Chlorpromazine is commonly associated with acute liver injury, with an incidence greater than 100 per 100,000 users [50-52]. The indication of chlorpromazine-induced liver injury is primarily cholestatic, but the hepatocellular injury marked by elevations in aminotransferase levels has also been reported in some chlorpromazine users [52, 53]. Although the mechanism of chlorpromazine-associated hepatotoxicity has not been elucidated, it has been suggested that reactive metabolites generated through CYP-mediated pathways may play a role [54].

Chlorpromazine has been classified as a less-DILI-concern drug with mild DILI severity [39]. The plasma level of chlorpromazine can reach up to 0.94 μ M with a therapeutic dose of 400-800 mg/day [55]. As shown in Fig. 2B, in EV controls, cell viability was markedly decreased as the

concentration of chlorpromazine increased to 12.5 μ M and higher levels. Moreover, metabolic detoxification of chlorpromazine was apparently mediated by all tested CYP isoforms, as indicated by enhanced cell viability in those CYP-overexpressing HepG2 cells in comparison to EV controls, implicating the involvement of these CYP enzymes in the production of less- or non-toxic metabolites.

Chlorpromazine is known to be extensively metabolized to a number of metabolites, and various CYP enzymes are involved in the biotransformation of chlorpromazine [56, 57]. For instance, CYP2D6 and CYP1A2 mediate the 7-hydroxylation and *N*-oxidation of chlorpromazine, and the former is the major metabolic pathway for chlorpromazine in humans [58-60]. CYP1A2 and CYP3A4 primarily contribute to 5-sulfoxidation of chlorpromazine, whereas CYP2B6, CYP2C19 and CYP2D6 make a minor contribution [61]. CYP1A2 is also responsible for the mono- and di-*N*-demethylation of chlorpromazine, while CYP2C19, CYP2B6 and CYP3A4 play notable roles in the mono- and di-*N*-demethylation at high concentrations of the drug [61]. Some of these metabolites may contribute to chlorpromazine hepatotoxicity [62]. It has been suggested that the hydroxylated metabolites of chlorpromazine are more active than the sulfoxide metabolites in inducing jaundice [63]. It has also been shown that the mono- and di-demethylated metabolites of chlorpromazine are three and six times, respectively, more potent than the parent drug in causing the leakage of aspartate aminotransferase from isolated rat hepatocytes, while 7- and 8-hydroxychlorpromazine are slightly less potent than chlorpromazine, and sulfoxide metabolites are inactive [64]. Our data suggest that chlorpromazine may be inactivated by a series of CYP enzymes, and MacAllister *et al.* [54] noted that chlorpromazine detoxification in rat hepatocytes also required glutathione and glucuronide pathways. The toxicity of a drug is a result of functional balance among the activation, detoxification, and secretion processes that are regulated by a number of genes involved in phase I, phase II, and phase III metabolism and in drug transport. It is also important to develop a system that expresses the majority of drug metabolizing and transporter genes to investigate hepatic drug metabolism and toxicity as a whole, which is warranted for our future study.

3.4. Cytotoxic effects of primaquine

Primaquine, an 8-aminoquinoline, is the only drug licensed by the U.S. FDA for the radical cure of *Plasmodium vivax* infection [65]. Despite a unique role in the treatment of *vivax* malaria, the use of primaquine is limited due to its hemolytic toxicity, particularly in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals [66]. In addition, recurrence of *P. vivax* occurs in up to 25% of patients following primaquine treatment, resulting from a lack of primaquine efficacy [67]. Although primaquine has been used since the 1950s, the mechanisms underlying its efficacy and toxicity remain elusive. It is thought that interference with the respiratory chain of parasite's mitochondria or production of redox active metabolite(s) may be involved in the efficacy and toxicity of primaquine [68, 69].

Primaquine has been designated as a no-DILI-concern drug due to the lack of associated DILI events [39]. The maximum plasma concentrations (C_{max}) of primaquine achieved in healthy subjects after administration of a therapeutic dose are around 0.20 μ M (15 mg base), 0.40 μ M (30 mg base) and 0.68 μ M (45 mg base) [70]. In our cytotoxicity assays, no toxic effects were observed at concentrations lower than 75 μ M (> 100 -fold C_{max}) primaquine in the majority of the HepG2-CYP cell lines (Fig. 2C). However, primaquine caused significant cytotoxicity in HepG2 cells overexpressing CYP2D6 and CYP1A1 in the range of concentrations tested. To determine the threshold concentrations for cytotoxicity in the two cell lines, lower concentrations of primaquine were subsequently employed. A significant decrease of cell viability was observed at as low as 0.31 μ M (Fig. 3A) and 5 μ M (Fig. 3B) primaquine in HepG2 cells overexpressing CYP2D6 and CYP1A1, respectively. The cytotoxicity of primaquine caused by the overexpression of CYP2D6 may be of pharmacological and toxicological significance since the treatment concentration is relevant to the concentration of the drug in the plasma, which is typically around 0.4 μ M.

The metabolic profile of primaquine has been investigated for decades but is still not fully elucidated. Carboxyprimaquine has been identified as the major metabolite of primaquine in humans, but it lacks antimalarial activity and toxicity [71-73]. On the other hand, hydroxylated metabolites of primaquine, such as 5-hydroxyprimaquine, have been suggested to be responsible for the efficacy and toxicity of the drug, due to their capability of generating reactive oxygen species through redox cycling [69, 74-77]. The CYP system is implicated in the metabolism of primaquine. It has been shown that multiple CYP isoforms, including CYP3A4, CYP2D6, CYP2B6, CYP1A2 and CYP2E1, variably contributed to the oxidative toxicity of primaquine [78]. However, recent studies have demonstrated that CYP2D6 plays a major role in the production of hydroxylated metabolites and makes an essential contribution to the metabolic activation of primaquine [79, 80]. The study by Bennett *et al.* [81] has revealed that malaria relapse rate is increased with a decreased metabolism of primaquine in poor/intermediate CYP2D6 metabolizers, suggesting that primaquine efficacy may depend on CYP2D6 activity. The significant cytotoxic effect of primaquine mediated by CYP2D6, as observed in our study, provides further evidence that CYP2D6 may have a primary role in generating active metabolites that are responsible for the efficacy and toxicity of primaquine. It is noteworthy that CYP2D6 is highly polymorphic with a substantial inter-individual variability (> 50 -fold) in activity within a population [82]. The dependence of primaquine bioactivation *via* a CYP2D6-mediated metabolic pathway highlights the importance of stratifying CYP2D6 metabolizer phenotypes or genotypes prior to primaquine treatment.

Interestingly, we also observed a remarkable cytotoxicity of primaquine in HepG2 cells overexpressing CYP1A1, which might be related to an increased stability of CYP1A1 transcripts by the primaquine treatment. Several studies showed that primaquine upregulated CYP1A1 expression at transcriptional and post-transcriptional levels [83-85]. Notably, Werlinder *et al.* [84] demonstrated that primaquine inhibited the degradation of CYP1A1 in a dose-dependent

manner. In their study, CYP1A1 degradation was dramatically inhibited by 10 μ M or higher concentrations of primaquine, which is consistent with our observation that primaquine exhibited remarkable cytotoxic effects at concentrations higher than 10 μ M in CYP1A1-overexpressing cells. The binding of primaquine at the active site of CYP1A1 has been postulated as a mechanism by which the drug protects CYP1A1 degradation. However, we did not observe the same effect for CYP1A2, suggesting that the regulatory mechanism may be specific for CYP1A1.

4. Summary

In summary, we generated a metabolically competent cell system by stable transduction of CYP cDNAs individually. We also showed the potential of the system for *in vitro* screening of metabolism-related drug toxicity. Such an *in vitro* assay system represents a useful paradigm for the evaluation and early detection of drug toxicity. Considering the large variations in metabolic phenotypes observed within and among human populations that impact the use of normal human hepatocytes in pharmacological studies *in vitro*, the use of a panel of cells that allows the characterization of the role of a specific metabolizing enzyme in drug biotransformation could be critical to avoid confounding issues due to inter-individual variability. The battery of cell lines described in this report, which express CYPs separately, could be a promising tool for the screening of drug metabolism and the assessment of the contribution of a particular CYP to drug-induced hepatotoxicity. Our cell system is readily available for further drug metabolism and hepatotoxicity studies.

Acknowledgements

JX and SC were supported by appointments to the Postgraduate Research Program at the National Center for Toxicological Research administered by the Oak Ridge Institute for Science Education through an interagency agreement between the U.S. Department of Energy and the U.S. FDA.

This article is not an official guidance or policy statement of the U.S. FDA. No official support or endorsement by the U.S. FDA is intended or should be inferred.

References

- [1] N. Kaplowitz, Idiosyncratic drug hepatotoxicity, *Nature reviews. Drug discovery*, 4 (2005) 489-499.
- [2] H. Jaeschke, M.R. McGill, A. Ramachandran, Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity, *Drug metabolism reviews*, 44 (2012) 88-106.
- [3] C. Ju, T. Reilly, Role of immune reactions in drug-induced liver injury (DILI), *Drug metabolism reviews*, 44 (2012) 107-115.
- [4] L. Yuan, N. Kaplowitz, Mechanisms of drug-induced liver injury, *Clinics in liver disease*, 17 (2013) 507-518, vii.
- [5] S. Chen, W.B. Melchior, Jr., L. Guo, Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity, *Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews*, 32 (2014) 83-104.
- [6] B.K. Gunawan, N. Kaplowitz, Mechanisms of drug-induced liver disease, *Clin Liver Dis*, 11 (2007) 459-475, v.
- [7] R.J. Andrade, J.A. Agundez, M.I. Lucena, C. Martinez, R. Cueto, E. Garcia-Martin, Pharmacogenomics in drug induced liver injury, *Current drug metabolism*, 10 (2009) 956-970.
- [8] S. Russmann, A. Jetter, G.A. Kullak-Ublick, Pharmacogenetics of drug-induced liver injury, *Hepatology*, 52 (2010) 748-761.
- [9] S.M. Huang, J.M. Strong, L. Zhang, K.S. Reynolds, S. Nallani, R. Temple, S. Abraham, S.A. Habet, R.K. Baweja, G.J. Burckart, S. Chung, P. Colangelo, D. Frucht, M.D. Green, P. Hepp, E. Karnaukhova, H.S. Ko, J.I. Lee, P.J. Marroum, J.M. Norden, W. Qiu, A. Rahman, S. Sobel, T. Stifano, K. Thummel, X.X. Wei, S. Yasuda, J.H. Zheng, H. Zhao, L.J. Lesko, New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process, *J Clin Pharmacol*, 48 (2008) 662-670.
- [10] E.L. LeCluyse, Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation, *Eur J Pharm Sci*, 13 (2001) 343-368.
- [11] A.P. Li, Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes, *Methods Mol Biol*, 640 (2010) 281-294.
- [12] P. Godoy, N.J. Hewitt, U. Albrecht, M.E. Andersen, N. Ansari, S. Bhattacharya, J.G. Bode, J. Bolleyn, C. Borner, J. Bottger, A. Braeuning, R.A. Budinsky, B. Burkhardt, N.R. Cameron, G. Camussi, C.S. Cho, Y.J. Choi, J. Craig Rowlands, U. Dahmen, G. Damm, O. Dirsch, M.T. Donato, J. Dong, S. Dooley, D. Drasdo, R. Eakins, K.S. Ferreira, V. Fonsato, J. Fraczek, R. Gebhardt, A. Gibson, M. Glanemann, C.E. Goldring, M.J. Gomez-Lechon, G.M. Groothuis, L. Gustavsson, C. Guyot, D. Hallifax, S. Hammad, A. Hayward, D. Haussinger, C. Hellerbrand, P. Hewitt, S. Hoehme, H.G. Holzhutter, J.B. Houston, J. Hrach, K. Ito, H. Jaeschke, V. Keitel, J.M. Kelm, B. Kevin Park, C. Kordes, G.A. Kullak-Ublick, E.L. LeCluyse, P. Lu, J. Luebke-Wheeler, A. Lutz, D.J. Maltman, M. Matz-Soja, P. McMullen, I. Merfort, S. Messner, C. Meyer, J. Mwinyi, D.J. Naisbitt, A.K. Nussler, P. Olinga, F. Pampaloni, J. Pi, L. Pluta, S.A. Przyborski, A. Ramachandran, V. Rogiers, C. Rowe, C. Schelcher, K. Schmich, M. Schwarz, B. Singh, E.H. Stelzer, B. Stieger, R. Stober, Y. Sugiyama, C. Tetta, W.E. Thasler, T. Vanhaecke, M. Vinken, T.S. Weiss, A. Widera, C.G. Woods, J.J. Xu, K.M. Yarborough, J.G. Hengstler, Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME, *Arch Toxicol*, 87 (2013) 1315-1530.
- [13] M.T. Donato, A. Lahoz, J.V. Castell, M.J. Gomez-Lechon, Cell lines: a tool for in vitro drug metabolism studies, *Current drug metabolism*, 9 (2008) 1-11.
- [14] L. Guo, S. Dial, L. Shi, W. Branham, J. Liu, J.L. Fang, B. Green, H. Deng, J. Kaput, B. Ning, Similarities and differences in the expression of drug-metabolizing enzymes between human

hepatic cell lines and primary human hepatocytes, *Drug metabolism and disposition: the biological fate of chemicals*, 39 (2011) 528-538.

[15] A. Iwamura, T. Fukami, H. Hosomi, M. Nakajima, T. Yokoi, CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay, *Drug metabolism and disposition: the biological fate of chemicals*, 39 (2011) 838-846.

[16] A. Zahno, K. Brecht, R. Morand, S. Maseneni, M. Torok, P.W. Lindinger, S. Krahenbuhl, The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells, *Biochemical pharmacology*, 81 (2011) 432-441.

[17] H. Hosomi, T. Fukami, A. Iwamura, M. Nakajima, T. Yokoi, Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation, *Drug metabolism and disposition: the biological fate of chemicals*, 39 (2011) 1388-1395.

[18] S. Yoshitomi, K. Ikemoto, J. Takahashi, H. Miki, M. Namba, S. Asahi, Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology, *Toxicology in vitro : an international journal published in association with BIBRA*, 15 (2001) 245-256.

[19] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, *Methods*, 25 (2001) 402-408.

[20] W.M. Lee, Drug-induced hepatotoxicity, *The New England journal of medicine*, 349 (2003) 474-485.

[21] B. Gunawan, N. Kaplowitz, Clinical perspectives on xenobiotic-induced hepatotoxicity, *Drug metabolism reviews*, 36 (2004) 301-312.

[22] D.J. Antoine, D.P. Williams, B.K. Park, Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science, *Expert opinion on drug metabolism & toxicology*, 4 (2008) 1415-1427.

[23] S.M. Attia, Deleterious effects of reactive metabolites, *Oxidative medicine and cellular longevity*, 3 (2010) 238-253.

[24] A. Srivastava, J.L. Maggs, D.J. Antoine, D.P. Williams, D.A. Smith, B.K. Park, Role of reactive metabolites in drug-induced hepatotoxicity, *Handbook of experimental pharmacology*, (2010) 165-194.

[25] J. Bai, A.I. Cederbaum, Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity, *Molecular and cellular biochemistry*, 262 (2004) 165-176.

[26] L. Vignati, E. Turlizzi, S. Monaci, P. Grossi, R. Kanter, M. Monshouwer, An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics, *Toxicology*, 216 (2005) 154-167.

[27] Q.G. Yan, J.G. Shi, F. Zhang, Q.T. Zhao, X.W. Pang, R. Chen, P.Z. Hu, Q.L. Li, Z. Wang, G.S. Huang, Overexpression of CYP2E1 enhances sensitivity of hepG2 cells to fas-mediated cytotoxicity, *Cancer biology & therapy*, 7 (2008) 1280-1287.

[28] B.B. Knowles, C.C. Howe, D.P. Aden, Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen, *Science*, 209 (1980) 497-499.

[29] F.J. Gonzalez, K.R. Korzekwa, Cytochromes P450 expression systems, *Annual review of pharmacology and toxicology*, 35 (1995) 369-390.

[30] A.S. Cockrell, T. Kafri, Gene delivery by lentivirus vectors, *Molecular biotechnology*, 36 (2007) 184-204.

[31] S.M. Zamule, S.C. Strom, C.J. Omiecinski, Preservation of hepatic phenotype in lentiviral-transduced primary human hepatocytes, *Chemico-biological interactions*, 173 (2008) 179-186.

[32] M. Nasri, A. Karimi, M. Allahbakhshian Farsani, Production, purification and titration of a lentivirus-based vector for gene delivery purposes, *Cytotechnology*, 66 (2014) 1031-1038.

[33] D. Skalamera, M. Dahmer, A.S. Purdon, B.M. Wilson, M.V. Ranall, A. Blumenthal, B. Gabrielli, T.J. Gonda, Generation of a genome scale lentiviral vector library for EF1alpha

promoter-driven expression of human ORFs and identification of human genes affecting viral titer, *PloS one*, 7 (2012) e51733.

[34] P. Vassallo, R.G. Trohman, Prescribing amiodarone: an evidence-based review of clinical indications, *Jama*, 298 (2007) 1312-1322.

[35] P. Santangeli, L. Di Biase, J.D. Burkhardt, R. Bai, P. Mohanty, A. Pump, A. Natale, Examining the safety of amiodarone, *Expert opinion on drug safety*, 11 (2012) 191-214.

[36] J.H. Lewis, R.C. Ranard, A. Caruso, L.K. Jackson, F. Mullick, K.G. Ishak, L.B. Seeff, H.J. Zimmerman, Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients, *Hepatology*, 9 (1989) 679-685.

[37] M. Babatin, S.S. Lee, P.T. Pollak, Amiodarone hepatotoxicity, *Current vascular pharmacology*, 6 (2008) 228-236.

[38] M. Richer, S. Robert, Fatal hepatotoxicity following oral administration of amiodarone, *The Annals of pharmacotherapy*, 29 (1995) 582-586.

[39] M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang, W. Tong, FDA-approved drug labeling for the study of drug-induced liver injury, *Drug discovery today*, 16 (2011) 697-703.

[40] S. Pourbaix, Y. Berger, J.P. Desager, M. Pacco, C. Harvengt, Absolute bioavailability of amiodarone in normal subjects, *Clinical pharmacology and therapeutics*, 37 (1985) 118-123.

[41] R.J. Flanagan, G.C. Storey, D.W. Holt, P.B. Farmer, Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients, *The Journal of pharmacy and pharmacology*, 34 (1982) 638-643.

[42] J.F. Brien, S. Jimmo, F.J. Brennan, S.E. Ford, P.W. Armstrong, Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues, *Canadian journal of physiology and pharmacology*, 65 (1987) 360-364.

[43] S.A. Gross, S. Bandyopadhyay, J.E. Klaunig, P. Somani, Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture, *Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine*, 190 (1989) 163-169.

[44] K.M. Waldhauser, M. Torok, H.R. Ha, U. Thomet, D. Konrad, K. Brecht, F. Follath, S. Krahenbuhl, Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives, *The Journal of pharmacology and experimental therapeutics*, 319 (2006) 1413-1423.

[45] A.E. Ratz Bravo, J. Drewe, R.G. Schlienger, S. Krahenbuhl, H. Pargger, W. Ummerhofer, Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature, *Critical care medicine*, 33 (2005) 128-134; discussion 245-126.

[46] M.E. Elsherbiny, A.O. El-Kadi, D.R. Brocks, The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole, *Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques*, 11 (2008) 147-159.

[47] P. KOZLIK, Metabolism of Amiodarone-Biotransformation of mono-N-Desethylamiodarone in-vitro, ETH Zurich, Switzerland, 2003.

[48] H.R. Ha, L. Bigler, B. Wendt, M. Maggiorini, F. Follath, Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients, *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, 24 (2005) 271-279.

[49] WHO, WHO Model List of Essential Medicines, 18th ed., (2013)
<http://www.who.int/medicines/publications/essentialmedicines/en/>.

[50] L.A. Garcia Rodriguez, A. Ruigomez, H. Jick, A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom, *Pharmacotherapy*, 17 (1997) 721-728.

[51] F.J. de Abajo, D. Montero, M. Madurga, L.A. Garcia Rodriguez, Acute and clinically relevant drug-induced liver injury: a population based case-control study, *British journal of clinical pharmacology*, 58 (2004) 71-80.

- [52] M. Sabate, L. Ibanez, E. Perez, X. Vidal, M. Buti, X. Xiol, A. Mas, C. Guarner, M. Forne, R. Sola, J. Castellote, J. Rigau, J.R. Laporte, Risk of acute liver injury associated with the use of drugs: a multicentre population survey, *Alimentary pharmacology & therapeutics*, 25 (2007) 1401-1409.
- [53] W.H. Munyon, R. Salo, D.F. Briones, Cytotoxic effects of neuroleptic drugs, *Psychopharmacology*, 91 (1987) 182-188.
- [54] S.L. MacAllister, C. Young, A. Guzdek, N. Zhidkov, P.J. O'Brien, Molecular cytotoxic mechanisms of chlorpromazine in isolated rat hepatocytes, *Canadian journal of physiology and pharmacology*, 91 (2013) 56-63.
- [55] L. Rivera-Calimlim, H. Nasrallah, J. Strauss, L. Lasagna, Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels, *The American journal of psychiatry*, 133 (1976) 646-652.
- [56] P. Turano, W.J. Turner, A.A. Manian, Thin-layer chromatography of chlorpromazine metabolites. Attempt to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics, *Journal of chromatography*, 75 (1973) 277-293.
- [57] M. Chetty, S.V. Moodley, R. Miller, Important metabolites to measure in pharmacodynamic studies of chlorpromazine, *Therapeutic drug monitoring*, 16 (1994) 30-36.
- [58] F. Hartmann, L.D. Gruenke, J.C. Craig, D.M. Bissell, Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man, *Drug metabolism and disposition: the biological fate of chemicals*, 11 (1983) 244-248.
- [59] J.R. Cashman, Z. Yang, L. Yang, S.A. Wrigton, Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes, *Drug metabolism and disposition: the biological fate of chemicals*, 21 (1993) 492-501.
- [60] K. Yoshii, K. Kobayashi, M. Tsumuji, M. Tani, N. Shimada, K. Chiba, Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes, *Life sciences*, 67 (2000) 175-184.
- [61] J. Wojcikowski, J. Boksa, W.A. Daniel, Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines, *Biochemical pharmacology*, 80 (2010) 1252-1259.
- [62] K. Selim, N. Kaplowitz, Hepatotoxicity of psychotropic drugs, *Hepatology*, 29 (1999) 1347-1351.
- [63] R.G. Watson, A. Olomu, D. Clements, R.H. Waring, S. Mitchell, E. Elias, A proposed mechanism for chlorpromazine jaundice--defective hepatic sulfoxidation combined with rapid hydroxylation, *Journal of hepatology*, 7 (1988) 72-78.
- [64] C.O. Abernathy, L. Lukacs, H.J. Zimmerman, Adverse effects of chlorpromazine metabolites on isolated hepatocytes, *Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine*, 155 (1977) 474-478.
- [65] D.R. Hill, J.K. Baird, M.E. Parise, L.S. Lewis, E.T. Ryan, A.J. Magill, Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I, *The American journal of tropical medicine and hygiene*, 75 (2006) 402-415.
- [66] R.J. Dern, E. Beutler, A.S. Alving, The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity, *The Journal of laboratory and clinical medicine*, 45 (1955) 30-39.
- [67] G.K. John, N.M. Douglas, L. von Seidlein, F. Nosten, J.K. Baird, N.J. White, R.N. Price, Primaquine radical cure of *Plasmodium vivax*: a critical review of the literature, *Malaria journal*, 11 (2012) 280.
- [68] P.H. Schlesinger, D.J. Krogstad, B.L. Herwaldt, Antimalarial agents: mechanisms of action, *Antimicrobial agents and chemotherapy*, 32 (1988) 793-798.
- [69] J. Vasquez-Vivar, O. Augusto, Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling, *The Journal of biological chemistry*, 267 (1992) 6848-6854.

- [70] G.W. Mihaly, S.A. Ward, G. Edwards, D.D. Nicholl, M.L. Orme, A.M. Breckenridge, Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size, *British journal of clinical pharmacology*, 19 (1985) 745-750.
- [71] G.W. Mihaly, S.A. Ward, G. Edwards, M.L. Orme, A.M. Breckenridge, Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite, *British journal of clinical pharmacology*, 17 (1984) 441-446.
- [72] M.D. Bates, S.R. Meshnick, C.I. Sigler, P. Leland, M.R. Hollingdale, In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of *Plasmodium berghei*, *The American journal of tropical medicine and hygiene*, 42 (1990) 532-537.
- [73] C.M. Link, A.D. Theoharides, J.C. Anders, H. Chung, C.J. Canfield, Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates, *Toxicology and applied pharmacology*, 81 (1985) 192-202.
- [74] J.L. Vennerstrom, J.W. Eaton, Oxidants, oxidant drugs, and malaria, *Journal of medicinal chemistry*, 31 (1988) 1269-1277.
- [75] K.A. Fletcher, P.F. Barton, J.A. Kelly, Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine, *Biochemical pharmacology*, 37 (1988) 2683-2690.
- [76] Z.S. Bowman, J.E. Oatis, Jr., J.L. Whelan, D.J. Jollow, D.C. McMillan, Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine, *The Journal of pharmacology and experimental therapeutics*, 309 (2004) 79-85.
- [77] Z.S. Bowman, J.D. Morrow, D.J. Jollow, D.C. McMillan, Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine, *The Journal of pharmacology and experimental therapeutics*, 314 (2005) 838-845.
- [78] S. Ganesan, B.L. Tekwani, R. Sahu, L.M. Tripathi, L.A. Walker, Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes, *Toxicology and applied pharmacology*, 241 (2009) 14-22.
- [79] B.S. Pybus, J.C. Sousa, X. Jin, J.A. Ferguson, R.E. Christian, R. Barnhart, C. Vuong, R.J. Sciotti, G.A. Reichard, M.P. Kozar, L.A. Walker, C. Ohrt, V. Melendez, CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine, *Malaria journal*, 11 (2012) 259.
- [80] B.S. Pybus, S.R. Marcisin, X. Jin, G. Deye, J.C. Sousa, Q. Li, D. Caridha, Q. Zeng, G.A. Reichard, C. Ockenhouse, J. Bennett, L.A. Walker, C. Ohrt, V. Melendez, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6, *Malaria journal*, 12 (2013) 212.
- [81] J.W. Bennett, B.S. Pybus, A. Yadava, D. Tosh, J.C. Sousa, W.F. McCarthy, G. Deye, V. Melendez, C.F. Ockenhouse, Primaquine failure and cytochrome P-450 2D6 in *Plasmodium vivax* malaria, *The New England journal of medicine*, 369 (2013) 1381-1382.
- [82] S.F. Zhou, Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, *Clinical pharmacokinetics*, 48 (2009) 689-723.
- [83] F. Fontaine, C. Delescluse, G. de Sousa, P. Lesca, R. Rahmani, Cytochrome 1A1 induction by primaquine in human hepatocytes and HepG2 cells: absence of binding to the aryl hydrocarbon receptor, *Biochemical pharmacology*, 57 (1999) 255-262.
- [84] V. Werlinder, M. Backlund, A. Zhukov, M. Ingelman-Sundberg, Transcriptional and post-translational regulation of CYP1A1 by primaquine, *The Journal of pharmacology and experimental therapeutics*, 297 (2001) 206-214.
- [85] T.E. Bapiro, T.B. Andersson, C. Otter, J.A. Hasler, C.M. Masimirembwa, Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells, *European journal of clinical pharmacology*, 58 (2002) 537-542.

Figure Legends

Fig. 1. Characterization of CYP expression in stably transduced HepG2 cells. (A) CYP mRNA expression. The mRNA levels of CYP isoforms in HepG2 cells stably transduced with individual CYP cDNAs or empty vector alone were measured by quantitative real-time PCR. Human β -actin was used as an internal control to normalize the amount of cDNA template. The fold expression of each CYP isoform relative to that in EV controls was determined by a comparative C_T method. Data represent the mean $\pm$ SD of three independent experiments. (B) CYP protein expression. The protein levels of cDNA-expressed CYP isoforms that range in molecular weight between 45 to 60 kDa were detected by western blotting. GAPDH (37 kDa) was used as a loading control. Similar expression pattern was observed in three independent experiments.

Fig. 2. Cytotoxicity of amiodarone (A), chlorpromazine (B) and primaquine (C) in HepG2 cells expressing individual human CYPs. CYP cDNAs or EV-transduced HepG2 cells were treated with three drugs at the indicated concentrations for 24 h. Cell viability was determined by the CellTiter-Glo assay after drug exposure. Similar results were observed in three independent experiments. The bar graphs represent mean $\pm$ SD of triplicate determinations. Statistical significance compared with EV controls: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

Fig. 3. Effects of CYP2D6 (A) and CYP1A1 (B) overexpression on primaquine cytotoxicity. HepG2 cells expressing CYP2D6 or CYP1A1 enzymes and control vector were exposed to various concentrations of primaquine for 24 h. The data are shown as mean $\pm$ SD of three independent experiments. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ compared with EV controls.

Table 1. Sequencing primers for recombinant CYP constructs.

Target	Sequence
CYP1A1	Forward: 5'-GGCCCGACCTCTACACCTTC-3' Reverse: 5'-TTGGATCTTTCTCTGTACCC-3'
CYP1A2	Forward: 5'-CCTTCTCCATCGCCTCTGAC-3' Reverse: 5'-TCTTCCTCTGTATCTCAGGC-3'
CYP1B1	Forward: 5'-CTTCACGCGCCAGCCGCGCAGC-3' Reverse: 5'-GCCAGGACATAGGGCAGGTTGG-3'
CYP2A6	Forward: 5'-TCATCGACGCCCTCCGGGGC-3' Reverse: 5'-TTCATGAGCAGCAAGAAGCC-3'
CYP2B6	Forward: 5'-GGCTCAGTGTCTGATAGAGG-3' Reverse: 5'-TGAGCATGAGCAGGAAGCCG-3'
CYP2C8	Forward: 5'-TGGGGAAGAGGAGCATTGAG-3' Reverse: 5'-TGCTTCAGCAGGAGCAGGAG-3'
CYP2C9	Forward: 5'-GACCGTGTTCAAGAGGAAGC-3' Reverse: 5'-TTCAGCAGGAGAAGGAGAGC-3'
CYP2C18	Forward: 5'-CCTGGGCTGTGCTCCCTGCA-3' Reverse: 5'-TTCAGCAGGAGCAGGAGTCC-3'
CYP2C19	Forward: 5'-CCAAGGCTTCACCCTGTGATC-3' Reverse: 5'-TTCAGCAGGAGAAGGAGAGC-3'
CYP2D6	Forward: 5'-GGAGCAGTGGGTGACCGAGG-3' Reverse: 5'-GATCATGAGCAGGAGGCCCC-3'
CYP2E1	Forward: 5'-GGAGGCCCACTTCCTGCTGG-3' Reverse: 5'-GGTATTTTCATGAGAATCAGG-3'
CYP3A4	Forward: 5'-TCTGAGGCGGGAAGCAGAGA-3' Reverse: 5'-GGACATCAGGGTGAGTGGCC-3'
CYP3A5	Forward: 5'-TGGTGAGAACTTGAGGCGG-3' Reverse: 5'-GGACATCAGGGTGAGTGGCC-3'
CYP3A7	Forward: 5'-GTTGGTGAGAAATCTGAGGCGG-3' Reverse: 5'-CAGTATCATAGGTGGGTGGTGC-3'
EF1 α -3'	Forward: 5'-TTGGATCTTGTTTCATTCTC-3'
IRES-5'	Reverse: 5'-AATAACATATAGACAAACGC-3'

Fig.1

(A)

(B)

CY	CY	CY	CY	CY	CY	CY
P1	P1	P1	P2	P2	P2	P2
A1	A2	B1	A6	B6	C8	C9

CYP isoforms

GAPDH

CY	CY	CY	CY	CY	CY	CY
P2	P2	P2	P2	P3	P3	P3
C1	C1	D6	E1	A4	A5	A7
8	9

CYP isoforms

GAPDH

Fig. 2 (A)

(B)

(C)

Fig. 3
(A)

(B)